glycine has been researched along with Blood Clot in 42 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to use a rabbit arterial thrombosis prevention and ear bleeding model to determine whether for equivalent efficacy, melagatran, a synthetic direct thrombin inhibitor, is safer than hirudin." | 7.72 | The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. ( Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI, 2003) |
| "The antithrombotic effects of direct (ximelagatran and hirudin) and indirect (dalteparin) anticoagulants were compared using a deep venous thrombosis (DVT) treatment model in conscious rats." | 7.71 | Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. ( Carlsson, S; Elg, M; Mattsson, C, 2002) |
| " The effects of LB-30057 on thrombus formation and hemostasis were evaluated in a veno-venous shunt model of thrombosis in rabbits, and compared with inogatran, another direct inhibitor of thrombin." | 7.71 | Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran. ( Bousley, RF; Chi, L; Gallagher, KP; Janiczek, N; Juneau, PL; Mertz, TE; Peng, YW; Rogers, KL; Saganek, L; Uprichard, AC, 2001) |
| "Inogatran (MW 439 Da), a new, selective, active site inhibitor of thrombin, was evaluated in three rat models of thrombosis." | 7.69 | Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. ( Börjesson, I; Elg, M; Gustafsson, D; Lenfors, S; Teger-Nilsson, AC, 1996) |
| " Herein, inspired by fibrinogen binding to activated platelets in thrombosis, this article reports a fibrinogen-mimicking, activated-platelet-sensitive nanocoacervate to enhance thrombus penetration of tissue plasminogen activator (tPA) for targeted thrombolytic therapy." | 4.12 | A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy. ( Chen, R; Guo, Y; Huang, Y; Jiang, J; Li, Y; Ren, J; Zhao, Q; Zhou, J, 2022) |
| "melagatran was started postoperatively and followed by oral ximelagatran was not more effective than enoxaparin started preoperatively." | 3.80 | Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. ( Eriksson, BI, 2003) |
| "We compared the antithrombotic properties of a factor Xa inhibitor (DX-9065a) with those of a thrombin inhibitor (melagatran) in a rat disseminated intravascular coagulation model and a rat venous thrombosis model." | 3.73 | Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. ( Furugohri, T; Honda, Y; Isobe, K; Matsumoto, C; Muramatsu, S; Shiozaki, Y; Sugiyama, N, 2005) |
| " The purpose of this study was to use a rabbit arterial thrombosis prevention and ear bleeding model to determine whether for equivalent efficacy, melagatran, a synthetic direct thrombin inhibitor, is safer than hirudin." | 3.72 | The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. ( Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI, 2003) |
| "The antithrombotic effects of direct (ximelagatran and hirudin) and indirect (dalteparin) anticoagulants were compared using a deep venous thrombosis (DVT) treatment model in conscious rats." | 3.71 | Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. ( Carlsson, S; Elg, M; Mattsson, C, 2002) |
| " The effects of LB-30057 on thrombus formation and hemostasis were evaluated in a veno-venous shunt model of thrombosis in rabbits, and compared with inogatran, another direct inhibitor of thrombin." | 3.71 | Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran. ( Bousley, RF; Chi, L; Gallagher, KP; Janiczek, N; Juneau, PL; Mertz, TE; Peng, YW; Rogers, KL; Saganek, L; Uprichard, AC, 2001) |
| "Inogatran (MW 439 Da), a new, selective, active site inhibitor of thrombin, was evaluated in three rat models of thrombosis." | 3.69 | Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. ( Börjesson, I; Elg, M; Gustafsson, D; Lenfors, S; Teger-Nilsson, AC, 1996) |
| "Melagatran has a wide therapeutic interval that enables it to be administered safely across a wide range of doses with no increased risk of bleeding, in contrast with warfarin whose narrow therapeutic window necessitates monitoring of its pharmacodynamic effect." | 2.42 | The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. ( Elg, M; Gustafsson, D, 2003) |
| " In experimental models of thrombosis, melagatran has been shown to have a shallower dose-response curve than warfarin and, therefore, a better separation between efficacy and bleeding." | 2.42 | Oral direct thrombin inhibitors in clinical development. ( Gustafsson, D, 2003) |
| "Ximelagatran has the potential to meet this need." | 2.42 | Orally active direct thrombin inhibitors. ( Weitz, J, 2003) |
| " Compared with placebo, platelet deposition and relative fibrin content were reduced after both heparin and melagatran, in the latter case with a dose-response relationship." | 1.32 | Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model. ( Björnheden, T; Carlsson, S; Grip, L; Mattsson, C; Scherstén, F; Wahlund, G, 2003) |
| "No potentiation of thrombus formation was observed when Feiba was added to melagatran, compared with controls." | 1.31 | Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. ( Carlsson, S; Elg, M; Gustafsson, D, 2001) |
| "A stable occlusive intracoronary thrombus was created in 19 dogs." | 1.29 | Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. ( Chen, L; Mattsson, C; Mehta, JL; Nichols, WW; Saldeen, TG; Teger-Nilsson, AC, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (14.29) | 18.7374 |
| 1990's | 5 (11.90) | 18.2507 |
| 2000's | 28 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y | 1 |
| Jiang, J | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Zhao, Q | 1 |
| Zhou, J | 1 |
| Li, Y | 1 |
| Chen, R | 1 |
| Yamamoto, N | 1 |
| Onoda, K | 1 |
| Zhao, J | 1 |
| Xu, Y | 1 |
| Xie, J | 1 |
| Liu, J | 1 |
| Zhang, R | 1 |
| Yan, X | 1 |
| Lassila, R | 1 |
| Harenberg, J | 2 |
| Zokai, K | 1 |
| Piazolo, L | 1 |
| Fenyvesi, T | 1 |
| Jörg, I | 1 |
| Carlsson, S | 4 |
| Elg, M | 5 |
| Mattsson, C | 3 |
| Haas, S | 2 |
| Scherstén, F | 1 |
| Wahlund, G | 1 |
| Björnheden, T | 1 |
| Grip, L | 1 |
| Gustafsson, D | 4 |
| Eriksson, BI | 1 |
| Klement, P | 1 |
| Rak, J | 1 |
| Liao, P | 1 |
| Vlasin, M | 1 |
| Stafford, A | 1 |
| Johnston, M | 1 |
| Weitz, JI | 2 |
| SALZMAN, EW | 1 |
| CHAMBERS, DA | 1 |
| Lebrazi, J | 1 |
| Elalamy, I | 1 |
| Samama, MM | 2 |
| Wolzt, M | 1 |
| Levi, M | 1 |
| Sarich, TC | 1 |
| Boström, SL | 1 |
| Eriksson, UG | 1 |
| Eriksson-Lepkowska, M | 1 |
| Svensson, M | 1 |
| Wåhlander, K | 1 |
| Weitz, J | 1 |
| Bauersachs, RM | 1 |
| de Laat, B | 1 |
| Derksen, RH | 1 |
| Urbanus, RT | 1 |
| de Groot, PG | 1 |
| Zee, RY | 1 |
| Hegener, HH | 1 |
| Gould, J | 1 |
| Ridker, PM | 1 |
| Furugohri, T | 1 |
| Shiozaki, Y | 1 |
| Muramatsu, S | 2 |
| Honda, Y | 1 |
| Matsumoto, C | 1 |
| Isobe, K | 1 |
| Sugiyama, N | 1 |
| Meyer Samama, M | 1 |
| Wehling, M | 1 |
| Jochmans, K | 1 |
| Lissens, W | 1 |
| Vervoort, R | 1 |
| Peeters, S | 1 |
| De Waele, M | 1 |
| Liebaers, I | 1 |
| Mimuro, J | 1 |
| Kaneko, M | 1 |
| Yoshitake, S | 1 |
| Iijima, K | 1 |
| Nakamura, K | 1 |
| Sakata, Y | 1 |
| Matsuda, M | 1 |
| Chen, L | 1 |
| Nichols, WW | 1 |
| Teger-Nilsson, AC | 2 |
| Saldeen, TG | 1 |
| Mehta, JL | 1 |
| Lenfors, S | 1 |
| Börjesson, I | 1 |
| Finkle, CD | 1 |
| St Pierre, A | 1 |
| Leblond, L | 1 |
| Deschenes, I | 1 |
| DiMaio, J | 1 |
| Winocour, PD | 1 |
| Liu, S | 1 |
| Edwards, DS | 1 |
| Harris, AR | 1 |
| Ziegler, MC | 1 |
| Poirier, MJ | 1 |
| Ewels, BA | 1 |
| Diluzio, WR | 1 |
| Hui, P | 1 |
| Chi, L | 1 |
| Mertz, TE | 1 |
| Rogers, KL | 1 |
| Janiczek, N | 1 |
| Peng, YW | 1 |
| Saganek, L | 1 |
| Bousley, RF | 1 |
| Juneau, PL | 1 |
| Uprichard, AC | 1 |
| Gallagher, KP | 1 |
| Heinzl, S | 1 |
| Lankes, W | 1 |
| Fleischer, K | 1 |
| Gulba, DC | 2 |
| Van Aken, H | 1 |
| Bode, C | 1 |
| Darius, H | 1 |
| Diehm, C | 1 |
| Encke, A | 1 |
| Hacke, W | 1 |
| Puhl, W | 1 |
| Quante, M | 1 |
| Riess, H | 1 |
| Scharf, R | 1 |
| Schellong, S | 1 |
| Schrör, T | 1 |
| Schulte, KL | 1 |
| Tebbe, U | 1 |
| Ozmen, L | 1 |
| Ekdahl, KN | 1 |
| Elgue, G | 1 |
| Larsson, R | 1 |
| Korsgren, O | 1 |
| Nilsson, B | 1 |
| Collins, WE | 1 |
| Mosher, DF | 1 |
| Tomasini, BR | 1 |
| Cooper, SL | 1 |
| Breddin, K | 1 |
| Grun, H | 1 |
| Scharrer, I | 1 |
| Krzywanek, J | 1 |
| Smith, GF | 1 |
| Murray, M | 1 |
| Kim, DN | 1 |
| Lee, KT | 1 |
| Jones, R | 1 |
| Thomas, WA | 1 |
| Lorand, JB | 1 |
| Pilkington, TR | 1 |
| Lorand, L | 1 |
10 reviews available for glycine and Blood Clot
| Article | Year |
|---|---|
[Thrombosis in spite of warfarin--what should be done?].
Topics: Anticoagulants; Antiphospholipid Syndrome; Azetidines; Benzylamines; Blood Coagulation; Glycine; Hep | 2001 |
The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
Topics: Azetidines; Benzylamines; Glycine; Hemostasis; Humans; Pharmacokinetics; Prodrugs; Thrombin; Thrombo | 2003 |
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Thromboe | 2003 |
Oral direct thrombin inhibitors in clinical development.
Topics: Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Glycine; Hemostasis; Humans; P | 2003 |
Orally active direct thrombin inhibitors.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Blood Coagulati | 2003 |
[Low molecular weight heparin, fondaparinux and melagatran: new data and clinical studies].
Topics: Angina, Unstable; Animals; Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin, | 2004 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylami | 2005 |
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benz | 2008 |
[Direct thrombin antagonists].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Antithromb | 2001 |
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzyla | 2001 |
2 trials available for glycine and Blood Clot
| Article | Year |
|---|---|
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Thromboe | 2003 |
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Topics: Adult; Azetidines; Benzylamines; Biomarkers; Blood Coagulation Tests; Dose-Response Relationship, Dr | 2004 |
31 other studies available for glycine and Blood Clot
| Article | Year |
|---|---|
A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.
Topics: Animals; Arginine; Aspartic Acid; Chitosan; Fibrinogen; Fibrinolytic Agents; Glycine; Hemorrhage; He | 2022 |
Intracardiac Thrombus Under Treatment With Daprodustat.
Topics: Barbiturates; Glycine; Heart Diseases; Humans; Thrombosis | 2023 |
Roxadustat Does Not Affect Platelet Production, Activation, and Thrombosis Formation.
Topics: Animals; Blood Coagulation; Blood Platelets; Case-Control Studies; Disease Models, Animal; Erythropo | 2021 |
Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
Topics: Antithrombin III; Azetidines; Benzylamines; Fibrin; Fibrinolytic Agents; Glycine; Heparin, Low-Molec | 2002 |
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response R | 2002 |
Melagatran. Exanta, H 319/68.
Topics: Animals; Azetidines; Benzylamines; Dogs; Fibrinolytic Agents; Glycine; Humans; Mice; Thrombosis | 2002 |
[New anticoagulants -- their clinical significance].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Biological Availability; Clinical Tr | 2003 |
[The first oral thrombin inhibitor. Competition to heparins and marcumar?].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Enoxaparin | 2003 |
Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model.
Topics: Angioplasty, Balloon, Coronary; Animals; Azetidines; Benzylamines; Blood Platelets; Coronary Vessels | 2003 |
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Topics: Animals; Arteries; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic | 2003 |
INHIBITION OF ADP-INDUCED PLATELET AGGREGATION BY SUBSTITUTED AMINO-ACIDS.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Alanine; Alkylation; Amino Acids; Aminocaproates; Aminoc | 1964 |
In vitro effect of melagatran and lepirudin on clot-bound thrombin.
Topics: Anticoagulants; Azetidines; Benzylamines; Glycine; Hirudins; Humans; In Vitro Techniques; Recombinan | 2003 |
[Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs].
Topics: Azetidines; Benzylamines; Glycine; Humans; Prodrugs; Thrombin; Thrombosis | 2004 |
IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.
Topics: Adult; Antibody Specificity; Arginine; beta 2-Glycoprotein I; Binding Sites, Antibody; Enzyme-Linked | 2005 |
Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis.
Topics: Amino Acid Substitution; Aspartic Acid; Case-Control Studies; Genetic Predisposition to Disease; Gly | 2005 |
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Disease Models, Animal; Dose-Response Relation | 2005 |
Antithrombin-Gly 424 Arg: a novel point mutation responsible for type 1 antithrombin deficiency and neonatal thrombosis.
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Arginine; Base Sequence; DNA; Female; Glycine; | 1994 |
An abnormal protein C (protein C Yonago) with an amino acid substitution of Gly for Arg-15 caused by a single base mutation of C to G in codon 57 (CGG-->GGG). Deteriorated calcium-dependent conformation of the gamma-carboxyglutamic acid domain relevant to
Topics: 1-Carboxyglutamic Acid; Amino Acid Sequence; Arginine; Base Sequence; Calcium; Codon; Glycine; Human | 1993 |
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
Topics: Animals; Dogs; Female; Glycine; Hemodynamics; Male; Molecular Weight; Piperidines; Thrombin; Thrombo | 1996 |
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Topics: Animals; Antithrombins; Arginine; Aspirin; Bleeding Time; Disease Models, Animal; Fibrinolytic Agent | 1996 |
BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Topics: Animals; Anticoagulants; Arginine; Arteries; Glycine; Heparin; Hirudins; Humans; Infusions, Intraven | 1998 |
Towards developing a non-SnCl2 formulation for RP444, a new radiopharmaceutical for thrombus imaging.
Topics: Chromatography, High Pressure Liquid; Glycine; Mannitol; Organotechnetium Compounds; Peptides, Cycli | 2001 |
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation; Blood Coagulati | 2001 |
Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran.
Topics: Animals; Benzamides; Bleeding Time; Disease Models, Animal; Dose-Response Relationship, Drug; Drug E | 2001 |
[New thrombolytic agents].
Topics: Anticoagulants; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Heparin; Humans; Thrombosis; | 2001 |
Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation.
Topics: ABO Blood-Group System; Aged; Aged, 80 and over; Anticoagulants; Azetidines; Benzylamines; Blood Pla | 2002 |
A preliminary comparison of the thrombogenic activity of vitronectin and other RGD-containing proteins when bound to surfaces.
Topics: Adsorption; Animals; Arginine; Aspartic Acid; Biocompatible Materials; Blood Proteins; Dogs; Glycine | 1987 |
The role of plasma factors in platelet aggregation.
Topics: Arteriosclerosis; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Platelets; Chemical | 1972 |
Thrombosis and blood coagulation. A study by quantitative N-terminal amino acid analysis.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Autoanalysis; Binding Sites; Blood Coagulation; Cattle | 1970 |
Studies of fibrinogen synthesis in rats fed thrombogenic diets.
Topics: Animals; Arachis; Blood Proteins; Butter; Carbon Isotopes; Cholesterol; Diet; Dietary Proteins; Fibr | 1966 |
Inhibitors of fibrin cross-linking: relevance for thrombolysis.
Topics: Blood Coagulation; Cyanides; Fibrin; Fibrinolytic Agents; Glycine; Thrombosis | 1966 |